x

Search for a clinical trial

* (*) mandatory field

200 Result(s)

Sort by

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member =

National clinical trial(s)

FRANCE

ILE-DE-FRANCE
PARIS

Ongoing trial
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire

FRANCE

ILE-DE-FRANCE
PARIS

Recruiting trial
Ongoing trial
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCE

ILE-DE-FRANCE
PARIS

GFM-Erlotinib-08 - Phase I-II trial of erlotinib in high risk myelodysplastic syndrome - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCE

ILE-DE-FRANCE
PARIS

Recruiting trial
Ongoing trial
A phase I-II study of the efficacy and safety of idarubicin combined to azacitidine in int-2 or high risk myelodysplastic syndromes.
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCE

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang

FRANCE

ILE-DE-FRANCE
PARIS

Recruiting trial
Ongoing trial
AZA-PLUS - Randomised phase II trial seeking the most promising drug association with azacitidine in higher risk myelodysplastic syndromes.
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors

FRANCE

ILE-DE-FRANCE
PARIS

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANY

Baden-Württemberg
FREIBURG

GERMANY

Baden-Württemberg
TÜBINGEN

Phase I/II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts in patients with treatment refractory hematologic malignancies - DE
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

GERMANY

Bayern
ERLANGEN

Exjade-Early-Trial: Early treatment with Deferasirox in low risk MDS - A prospective multicentre single-arm single-stage Phase II Study - DE
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 5 - Hämatologie und Internistische Onkologie

GERMANY

Bayern
MÜNCHEN

Recruiting trial
Ongoing trial
A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für Innere Medizin III

GERMANY

Nordrhein-Westfalen
DÜSSELDORF

GERMANY

Sachsen
DRESDEN

TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

TEMDS (TUD-TEMDS1-042): Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study (Phase II) - Terminated
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
GEPARD Study: A One Year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low probability of response
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
A Phase 2, open label, ascending dose study of ACE-536 for the treatment of anemia in patients with low or intermediate-1 risk Myelodysplastic Syndrome (PACE)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

NETHERLANDS

Gelderland
NIJMEGEN

NETHERLANDS

Zuid-Holland
LEIDEN

NETHERLANDS

Zuid-Holland
ROTTERDAM

Lenalidomide Versus Placebo in Myelodysplastic Syndromes with an Deletion-5q Abnormality
Erasmus MC - Erasmus Medisch Centrum
Afdeling Hematologie

SPAIN

Comunidad Valenciana
VALENCIA

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

SPAIN

Comunidad Valenciana
VALENCIA

UNITED KINGDOM

South Glamorgan
CARDIFF

Ongoing trial
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

South Glamorgan
CARDIFF

Recruiting trial
Ongoing trial
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

UNITED KINGDOM

South Glamorgan
CARDIFF

AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

AUSTRIA

OBERÖSTERREICH
LINZ

Recruiting trial
Ongoing trial
INSPIRE: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - AT
Ordensklinikum Linz GmbH Elisabethinen
Interne 1 - Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie

GERMANY

Sachsen
DRESDEN

Ongoing trial
Phase III multicenter, randomized, controlled study to assess efficacy and safety of ON 01910.Na in MDS Patients with excess blasts relapsing after or refractory to or intolerant to Azacitidine or Decitabine - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Ongoing trial
A phase III, multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediate-1 risk Myelodysplastic Syndrome - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANY

Sachsen
DRESDEN

Recruiting trial
Ongoing trial
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

SWITZERLAND

Suisse Alémanique
BERN

UNITED KINGDOM

Nottinghamshire
NOTTINGHAM

BELGIUM

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Ongoing trial
STEP: Sorafenib Long Term Extension Program - BE
Cliniques Universitaires UCL Saint-Luc
Pneumologie_Oncologie thoracique

Multinational clinical trial(s)

GERMANY

Berlin
ADDRESS: NOT PROVIDED - DE